Literature DB >> 27639448

Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Mason M Silveira1, Jonathon C Arnold2, Steven R Laviolette3, Cecilia J Hillard4, Marta Celorrio5, María S Aymerich6, Wendy K Adams7.   

Abstract

Public opinion surrounding the recreational use and therapeutic potential of cannabis is shifting. This review describes new work examining the behavioural and neural effects of cannabis and the endocannabinoid system, highlighting key regions within corticolimbic brain circuits. First, we consider the role of human genetic factors and cannabis strain chemotypic differences in contributing to interindividual variation in the response to cannabinoids, such as THC, and review studies demonstrating that THC-induced impairments in decision-making processes are mediated by actions at prefrontal CB1 receptors. We further describe evidence that signalling through prefrontal or ventral hippocampal CB1 receptors modulates mesolimbic dopamine activity, aberrations of which may contribute to emotional processing deficits in schizophrenia. Lastly, we review studies suggesting that endocannabinoid tone in the amygdala is a critical regulator of anxiety, and report new data showing that FAAH activity is integral to this response. Together, these findings underscore the importance of cannabinoid signalling in the regulation of cognitive and affective behaviours, and encourage further research given their social, political, and therapeutic implications.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AEA; Amygdala; Anxiety; CB(1) receptor; Cannabidiol; Cannabis; Corticolimbic circuits; Decision-making; Elevated plus maze; Emotional salience processing; Endocannabinoid system; FAAH; Hippocampus; Individual differences; Mesolimbic dopamine system; Phytocannabinoids; Prefrontal cortex; Psychiatric disorders; Social interaction; THC

Mesh:

Substances:

Year:  2016        PMID: 27639448      PMCID: PMC5350061          DOI: 10.1016/j.neubiorev.2016.09.007

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  205 in total

1.  Acute marijuana effects on human risk taking.

Authors:  Scott D Lane; Don R Cherek; Oleg V Tcheremissine; Lori M Lieving; Cythia J Pietras
Journal:  Neuropsychopharmacology       Date:  2005-04       Impact factor: 7.853

Review 2.  Cortical pathways to the mammalian amygdala.

Authors:  A J McDonald
Journal:  Prog Neurobiol       Date:  1998-06       Impact factor: 11.685

Review 3.  Common single nucleotide variants underlying drug addiction: more than a decade of research.

Authors:  Kora-Mareen Bühler; Elena Giné; Victor Echeverry-Alzate; Javier Calleja-Conde; Fernando Rodriguez de Fonseca; Jose Antonio López-Moreno
Journal:  Addict Biol       Date:  2015-01-21       Impact factor: 4.280

4.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

5.  Parvalbumin and GAD65 interneuron inhibition in the ventral hippocampus induces distinct behavioral deficits relevant to schizophrenia.

Authors:  Robin Nguyen; Mark D Morrissey; Vivek Mahadevan; Janine D Cajanding; Melanie A Woodin; John S Yeomans; Kaori Takehara-Nishiuchi; Jun Chul Kim
Journal:  J Neurosci       Date:  2014-11-05       Impact factor: 6.167

Review 6.  The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.

Authors:  David W Volk; David A Lewis
Journal:  Biol Psychiatry       Date:  2015-06-19       Impact factor: 13.382

7.  Estrogen recruits the endocannabinoid system to modulate emotionality.

Authors:  Matthew N Hill; Eda S Karacabeyli; Boris B Gorzalka
Journal:  Psychoneuroendocrinology       Date:  2007-03-27       Impact factor: 4.905

8.  Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

Authors:  Paolo Fusar-Poli; José A Crippa; Sagnik Bhattacharyya; Stefan J Borgwardt; Paul Allen; Rocio Martin-Santos; Marc Seal; Simon A Surguladze; Colin O'Carrol; Zerrin Atakan; Antonio W Zuardi; Philip K McGuire
Journal:  Arch Gen Psychiatry       Date:  2009-01

9.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

Review 10.  The endocannabinoid system in guarding against fear, anxiety and stress.

Authors:  Beat Lutz; Giovanni Marsicano; Rafael Maldonado; Cecilia J Hillard
Journal:  Nat Rev Neurosci       Date:  2015-12       Impact factor: 34.870

View more
  10 in total

1.  Interactions between cannabidiol and Δ9 -tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome.

Authors:  Lyndsey L Anderson; Ivan K Low; Iain S McGregor; Jonathon C Arnold
Journal:  Br J Pharmacol       Date:  2020-07-27       Impact factor: 8.739

2.  Adolescent Δ9-Tetrahydrocannabinol Exposure and Astrocyte-Specific Genetic Vulnerability Converge on Nuclear Factor-κB-Cyclooxygenase-2 Signaling to Impair Memory in Adulthood.

Authors:  Yan Jouroukhin; Xiaolei Zhu; Alexey V Shevelkin; Yuto Hasegawa; Bagrat Abazyan; Atsushi Saito; Jonathan Pevsner; Atsushi Kamiya; Mikhail V Pletnikov
Journal:  Biol Psychiatry       Date:  2018-08-16       Impact factor: 13.382

Review 3.  The why behind the high: determinants of neurocognition during acute cannabis exposure.

Authors:  Johannes G Ramaekers; Natasha L Mason; Lilian Kloft; Eef L Theunissen
Journal:  Nat Rev Neurosci       Date:  2021-05-27       Impact factor: 34.870

Review 4.  The Neuroscience of Drug Reward and Addiction.

Authors:  Nora D Volkow; Michael Michaelides; Ruben Baler
Journal:  Physiol Rev       Date:  2019-10-01       Impact factor: 37.312

Review 5.  Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research.

Authors:  Rafael N Ruggiero; Matheus T Rossignoli; Jana B De Ross; Jaime E C Hallak; Joao P Leite; Lezio S Bueno-Junior
Journal:  Front Pharmacol       Date:  2017-06-21       Impact factor: 5.810

6.  "Hallucinations" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs.

Authors:  Frederick S Barrett; Nicolas J Schlienz; Natalie Lembeck; Muhammad Waqas; Ryan Vandrey
Journal:  Cannabis Cannabinoid Res       Date:  2018-03-01

7.  Somatosensory amplification, health anxiety, and alexithymia in generalized anxiety disorder.

Authors:  Vijaya Kumar; Ajit Avasthi; Sandeep Grover
Journal:  Ind Psychiatry J       Date:  2018 Jan-Jun

8.  Changing the Tone of Clinical Study Design in the Cannabis Industry.

Authors:  Joseph M Antony; Alison C McDonald; Farshid Noorbakhsh; Najla Guthrie; Mal Evans
Journal:  Transl Neurosci       Date:  2020-02-13       Impact factor: 1.757

9.  Targeting the Endocannabinoid System in Borderline Personality Disorder: Corticolimbic and Hypothalamic Perspectives.

Authors:  Sari G Ferber; Reut Hazani; Gal Shoval; Aron Weller
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

10.  Cannabidiol Produces Distinct U-Shaped Dose-Response Effects on Cocaine-Induced Conditioned Place Preference and Associated Recruitment of Prelimbic Neurons in Male Rats.

Authors:  Hermina Nedelescu; Grant E Wagner; Genna L De Ness; Ayla Carroll; Tony M Kerr; Jingjun Wang; Saiwen Zhang; Stephen Chang; Amy H Than; Nora E Emerson; Nobuyoshi Suto; Friedbert Weiss
Journal:  Biol Psychiatry Glob Open Sci       Date:  2021-07-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.